AIRLINK 176.51 Decreased By ▼ -0.49 (-0.28%)
BOP 12.86 Increased By ▲ 0.05 (0.39%)
CNERGY 7.56 Increased By ▲ 0.07 (0.93%)
FCCL 45.55 Increased By ▲ 3.53 (8.4%)
FFL 15.18 Increased By ▲ 0.34 (2.29%)
FLYNG 27.20 Decreased By ▼ -0.50 (-1.81%)
HUBC 131.75 Decreased By ▼ -2.76 (-2.05%)
HUMNL 13.32 Increased By ▲ 0.36 (2.78%)
KEL 4.47 Increased By ▲ 0.03 (0.68%)
KOSM 6.06 No Change ▼ 0.00 (0%)
MLCF 56.40 Increased By ▲ 1.89 (3.47%)
OGDC 224.52 Increased By ▲ 1.94 (0.87%)
PACE 6.00 Decreased By ▼ -0.03 (-0.5%)
PAEL 41.42 Increased By ▲ 0.12 (0.29%)
PIAHCLA 16.10 Increased By ▲ 0.48 (3.07%)
PIBTL 9.89 Decreased By ▼ -0.17 (-1.69%)
POWER 11.10 Decreased By ▼ -0.07 (-0.63%)
PPL 186.85 Increased By ▲ 2.86 (1.55%)
PRL 34.93 Increased By ▲ 0.62 (1.81%)
PTC 23.60 Increased By ▲ 0.26 (1.11%)
SEARL 94.30 Increased By ▲ 3.23 (3.55%)
SILK 1.13 Increased By ▲ 0.02 (1.8%)
SSGC 34.66 Increased By ▲ 0.68 (2%)
SYM 15.64 Decreased By ▼ -0.32 (-2.01%)
TELE 7.90 Increased By ▲ 0.04 (0.51%)
TPLP 10.97 Decreased By ▼ -0.04 (-0.36%)
TRG 59.00 Increased By ▲ 0.28 (0.48%)
WAVESAPP 10.81 Increased By ▲ 0.02 (0.19%)
WTL 1.36 No Change ▼ 0.00 (0%)
YOUW 3.84 Increased By ▲ 0.03 (0.79%)
AIRLINK 176.51 Decreased By ▼ -0.49 (-0.28%)
BOP 12.86 Increased By ▲ 0.05 (0.39%)
CNERGY 7.56 Increased By ▲ 0.07 (0.93%)
FCCL 45.55 Increased By ▲ 3.53 (8.4%)
FFL 15.18 Increased By ▲ 0.34 (2.29%)
FLYNG 27.20 Decreased By ▼ -0.50 (-1.81%)
HUBC 131.75 Decreased By ▼ -2.76 (-2.05%)
HUMNL 13.32 Increased By ▲ 0.36 (2.78%)
KEL 4.47 Increased By ▲ 0.03 (0.68%)
KOSM 6.06 No Change ▼ 0.00 (0%)
MLCF 56.40 Increased By ▲ 1.89 (3.47%)
OGDC 224.52 Increased By ▲ 1.94 (0.87%)
PACE 6.00 Decreased By ▼ -0.03 (-0.5%)
PAEL 41.42 Increased By ▲ 0.12 (0.29%)
PIAHCLA 16.10 Increased By ▲ 0.48 (3.07%)
PIBTL 9.89 Decreased By ▼ -0.17 (-1.69%)
POWER 11.10 Decreased By ▼ -0.07 (-0.63%)
PPL 186.85 Increased By ▲ 2.86 (1.55%)
PRL 34.93 Increased By ▲ 0.62 (1.81%)
PTC 23.60 Increased By ▲ 0.26 (1.11%)
SEARL 94.30 Increased By ▲ 3.23 (3.55%)
SILK 1.13 Increased By ▲ 0.02 (1.8%)
SSGC 34.66 Increased By ▲ 0.68 (2%)
SYM 15.64 Decreased By ▼ -0.32 (-2.01%)
TELE 7.90 Increased By ▲ 0.04 (0.51%)
TPLP 10.97 Decreased By ▼ -0.04 (-0.36%)
TRG 59.00 Increased By ▲ 0.28 (0.48%)
WAVESAPP 10.81 Increased By ▲ 0.02 (0.19%)
WTL 1.36 No Change ▼ 0.00 (0%)
YOUW 3.84 Increased By ▲ 0.03 (0.79%)
BR100 12,120 Increased By 97.7 (0.81%)
BR30 37,239 Increased By 633.5 (1.73%)
KSE100 114,521 Increased By 807.9 (0.71%)
KSE30 35,490 Increased By 188.1 (0.53%)

KARACHI: As Pakistan’s pharmaceutical sector aims to leverage its potential for increased exports, industry experts are calling for government support to create an enabling environment for growth.

Key officials express that with the right policy framework, exports could rise dramatically from the current levels. Industry leaders pointed out that while sectors such as textiles, carpets, leather, sports goods, and surgical instruments receive preferential treatment, pharmaceuticals have not enjoyed similar benefits.

The current export facilitation framework appears to favour established sectors based on past performance, overlooking the substantial potential of pharmaceuticals, which could significantly contribute to foreign exchange inflows.

Pakistan Pharma Summit 2024: experts gather with aim to chart path for growth in pharmaceutical industry

Currently, Pakistan’s pharmaceutical industry has performed well in specific markets. Countries like Uzbekistan, Nigeria, and Afghanistan are among those where pharmaceuticals rank as major export commodities.

“Even based on existing performance, there are several countries where pharmaceutical products from Pakistan are the largest exported commodity,” underscoring the sector’s robust international footprint.

A former chairman of the Pakistan Pharmaceutical Manufacturers’ Association (PPMA) has already stated that the country’s pharmaceutical exports could reach $3 billion within the next five years if the government prioritises the sector in its export policies. In contrast, Indian pharmaceutical exports were projected to hit $28 billion, while Pakistan’s exports hit a historic high of just over $341 million in 2023-24.

Experts believed that a structured market development assistance (MDA) programme similar to India’s initiative could provide necessary support to local pharmaceutical companies.

Furthermore, they advocated for a thorough assessment of local API production capabilities before imposing duties, arguing that such measures can ensure affordability and competitiveness of Pakistani pharmaceutical products. The sector also faces challenges related to maintaining a stable supply chain and reliable raw material procurement, which are key to securing lasting agreements in foreign markets. As observed, foreign markets typically demand long-term contracts of up to seven years, creating a need for predictability in supply chains and procurement strategies.

With the government exploring avenues to generate foreign exchange and reduce dependency on debt, focusing on non-debt creating exports is critical. Analysts point out that despite significant rupee depreciation over recent years, the anticipated growth in exports has not materialized, suggesting that new strategies are necessary to unlock Pakistan’s export potential.

Copyright Business Recorder, 2024

Comments

Comments are closed.

Obaid Ali Nov 13, 2024 08:43pm
Functioning based on the incorrect hypothesis would be wrong. Don't be victim of ignorant. First and last word is Quality. No body ask anybody to manufacture poor quality drug. Be honest please
thumb_up Recommended (0)